Client news: eTheRNA Immunotherapeutics has raised 39M Euro in Series B2

Our client eTheRNA Immunotherapeutics announced that they have raised 39M Euro in a Series B2 financing round, in order to expand investment in their mRNA technology platform. The financing round was lead by Novalis LifeSciences, followed by their existing investors.

There were also a few internal shifts, with new board members such as Dr. Kenneth Chien, co-founder of Moderna Therapeutics and Dr. Marijn Dekkers, founder and chairman of Novalis LifeSciences. In addition, current COO Bernard Sagaert was appointed as interim-CEO, replacing Steven Powell.

Want to read more on this topic? Click here.

More on subject(s)   Follow us at LinkedIn

Stay up to date